Wedbush lowers Larimar Therapeutics stock price target on funding

Wedbush cut its price target on Larimar Therapeutics (LRMR) to $9 from $11, citing funding concerns, while maintaining an Outperform rating. The stock is up 19% in the past week. The company has $129M in cash, enough to last until late Q2 2027, but faces high cash burn. Wedbush expects BLA acceptance in January and potential fundraising in Q1 2027.

Original reporting
Published Nov 16, 2026, 3:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 3:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$LRMR
Bearish
high confidence
Mentioned
$LRMR
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LRMRBearishMed
01

Why it matters

Analyst downgrade reflects concerns over cash burn and regulatory timing, but the company retains a strong balance sheet.

02

Market read

Target reduction may trigger short‑term sell pressure in LRMR, while the broader biotech sector remains sensitive to regulatory milestones.

03

What to watch

Potential Priority Review Voucher and cash runway may support upside despite target reduction.

Relevance 6/10Novelty 6/10Timing: today

Background

Larimar Therapeutics reported $129 M cash, negative free cash flow, and a pending BLA submission for its drug nomlabofusp.

Company-level read

Ticker impact

$LRMRBearishHigh confidence
Context

Wedbush lowered its price target for Larimar Therapeutics to $9 from $11, maintaining an Outperform rating.

Expected impact

likely downward pressure as investors price in the reduced target.

Evidence & confidence

Target reduction is a fresh analyst action on a micro‑cap biotech; traders may adjust positions promptly.

Market effects

May dampen sentiment toward small‑cap biotech sector as analysts tighten expectations.

Limited to US‑listed biotech investors.

Low global impact; primarily affects LRMR shareholders.

Counterpoint

Target cut could be overly cautious if BLA acceptance occurs on schedule.

Key entities

  • Larimar Therapeutics Inc.

    NASDAQ‑listed biotech developing nomlabofusp for Friedreich’s ataxia.

  • Wedbush Securities

    Equity research firm that issued the target cut.

Related articles

$LRMRMed

Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update • Completed BLA submission seeking accelerated approval of nomlabofusp for adults and pediatric patients with FA; potential to be the first disease-modifying therapy to address root cause o

$LRMRMed

Larimar Therapeutics, Inc. (LRMR): Results of Operations and Financial Condition

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia • Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the under

$LRMRMed

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Larimar Therapeutics, Inc. (LRMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update • Positive longer-term open label study data further demonstrated nomlabofusp's well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinica

$LRMRMed

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

Larimar Therapeutics (NASDAQ:LRMR) filed the first module of its Biologics License Application with the U.S. FDA for Nomlabofusp therapy on an accelerated basis, with additional modules planned in the second half of 2026. The company cited positive open-label study results in adult Friedreich’s ataxia patients and said FDA confirmed existing data supports the submission using skin frataxin as a surrogate endpoint. Baird cut its price target to $5 from $7 while keeping an Outperform rating.